15MUSCULOSKELETAL DISORDERS

Zeel® T Zeel® T works by modulating both the 5-lipoxygenase (5-LOX) and COX-1 and -2 pathways. In the recent study by Sanchez et al. Zeel® T reduced several characteristics of OA in a multitarget way by potentially inhibiting cartilage degradation via matrix metallopeptidase 13 (MMP-13) associated pathways and stimulating chondrogenesis via the cellular communication network factor 1 (CCN1) pathway. [Sanchez 2021] For more information please refer to the Zeel® T product monograph.

Traumeel® and Zeel® T Through their multicomponent and unique formulations, Traumeel® and Zeel® T address multiple targets and pathways that aim to regulate and support the inflammatory network and the microenvironment. The combination of Traumeel® and Zeel® T acts as a multi-ingredient, multi-target immunomodulation product that principally influences cytokines and TGF-β to attenuate cellular immunity while enhancing bone and cartilage formation.

Together Traumeel® and Zeel® T address central aspects of knee OA to relieve pain and its underlying causes: Impaired inflammation (chronic inflammation of the articular and periarticular

structures).[Bonnet 2005]

Angiogenesis (formation of new blood vessels).[Bonnet 2005]

Joint degradation (alteration in cartilage structure).[Bonnet 2005]

Zeel® T supports cartilage by stimulating extracellular matrix production and may inhibit its degradation. [Sanchez 2021]

The MOZArT study demonstrates that Traumeel® and Zeel® T co-administered intra- articular injections are significantly superior to placebo in reducing knee pain in subjects with moderate-to-severe pain associated with knee osteoarthritis.[Lozada 2017]

For more information please refer to the monograph on Osteoarthritis of the Knee: a new effective treatment option with Traumeel® and Zeel® T injections.

Summary Osteoarthritis (OA) of the knee is a common condition. Pharmacological treatments for OA include NSAIDs, intra-articular (IA) injections

of steroids and IA-HA. To date there are no approved Disease-Modifying Osteoarthritis Drugs (DMOADs)

that can slow or alter the progression of OA. [Oo 2021]

Recent guidelines have suggested that these treatments are individually tailored according to individual patient comorbidities.

The role of inflammation in OA is now recognised. Through their multicomponent and unique formulations, Traumeel® and Zeel® T

address multiple targets and pathways to regulate inflammation. The MOZArT study demonstrates that Traumeel® and Zeel® T co-administered IA

injections are significantly superior to placebo in reducing knee pain in subjects with moderate-to-severe pain associated with knee OA.[Lozada 2017]